More patients with R132C (58%) and R132L/G/S (48%) mutations achieved an overall response compared to those with an R132H mutation (26%)...Although fewer patients in the overall responder groups had FLT3 or NPM1 mutations compared with the non-responder group, 12/38 (32%) with NPM1 and 5/16 (31%) with FLT3 had an overall response....This post-hoc analysis demonstrated that response to olutasidenib occurred across a wide variety of patient types and disease characteristics...